	US 12,076,442 B1
	Activated cannabinoid controlled release compound tablet and method of forming the same
Christopher R. Emerson, San Francisco, CA (US); Christopher M. Antapli, San Francisco, CA (US); and Flip Senn, Daly City, CA (US)
Assigned to METTA MEDICAL INC, San Francisco, CA (US)
Filed by Metta Medical Inc., San Francisco, CA (US)
Filed on Dec. 6, 2022, as Appl. No. 18/062,351.
Application 18/062,351 is a continuation of application No. 15/929,953, filed on May 29, 2020, granted, now 11,596,606.
Claims priority of provisional application 62/854,925, filed on May 30, 2019.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); B82Y 5/00 (2011.01); B82Y 40/00 (2011.01)

CPC A61K 9/2095 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); B82Y 5/00 (2013.01); B82Y 40/00 (2013.01)]

13 Claims

1. A method, comprising:

providing a cannabinoid in a solid form;

heating said cannabinoid to a temperature of about 95 to 100 degrees Celsius for approximately 45 to 60 minutes;

cooling said cannabinoid to a temperature less than about minus ten degrees Celsius for approximately 10 to 16 minutes;

mixing a mesoporous silica in a solid form with said cannabinoid to form a dry powdery activated cannabinoid controlled release compound;

mixing a super disintegrant, a vegan excipient and a lubricant with said activated cannabinoid controlled release compound; and

adding a terpenoid to and homogenized with said activated cannabinoid controlled release compound.